Does regulation drive out competition in pharmaceutical markets?

Journal of Law and Economics

Volumn 43, Issue 2, 2000, Pages 311-357

  Danzon, Patricia M ^a   Chao, Li Wei ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0034354072     PISSN: 00222186     EISSN: None     Source Type: Journal    
DOI: 10.1086/467458     Document Type: Article

References (31)

1. Alexander, Donald; Flynn, Joseph E; and Linkins, Linda A. "Estimates of the Demand for Ethical Pharmaceutical Drugs across Countries and Time." Applied Economics 26 (1994): 821-26.
2. Anessi, Eugenio Pessina. The Effect of User Charges on the Utilization of Prescription Medicines in the Italian National Health Service. Doctoral dissertation. Philadelphia: University of Pennsylvania, The Wharton School, 1997.
3. Baines, Darrin L; Tolley, Keith H.; and Whynes, David K. Prescribing Budgets and Fundholding in General Practice. London: Office of Health Economics, 1997.
4. Barral, P. Etienne. Twenty Years of Pharmaceutical Research Results throughout the World (1975-1994). Paris: Fondation Rhone-Poulenc Santé, 1995.
5. Boston Consulting Group. The Changing Environment for U.S. Pharmaceuticals. Boston: Boston Consulting Group, 1993.
6. Caves, Richard E.; Whinston, Michael D.; and Hurwitz, Mark A. "Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry." In Brookings Papers on Economic Activity: Microeconomics (1991), pp. 1-48.
7. Danzon, Patricia M. "Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU." International Journal of the Economics of Business 4 (1997): 301-22.
8. Danzon, Patricia M. Price Regulation in the Pharmaceutical Industry: National vs. Global Interests. Washington, D.C.: American Enterprise Institute Press, 1997.
9. Danzon, Patricia M. "Competition in the Off-Patent Sector: The US Experience." Pharma Pricing Review 3 (1998): 46-50.
10. Danzon, Patricia M., and Chao, Li-Wei. "Cross-National Price Differences for Pharmaceuticals: How Large and Why?" Journal of Health Economics 19 (2000): 159-96.
11. Danzon, Patricia M., and Kim, Jeong D. "Price Indexes for Pharmaceuticals: How Accurate are International Comparisons?" Working paper. Philadelphia: University of Pennsylvania, The Wharton School, 1996.
12. Danzon, Patricia M., and Kim, Jeong D. "International Price Comparisons for Pharmaceuticals: Measurement and Policy Issues." PharmacoEconomics 14 (1998): 115-28.
13. Danzon, Patricia M., and Liu, Hong. "Reference Pricing and Physician Drug Budgets: The German Experience in Controlling Pharmaceutical Expenditures." Working paper. Philadelphia: University of Pennsylvania, The Wharton School, 1998.
14. DiMasi, Joseph A., et al. "The Cost of Innovation in the Pharmaceutical Industry." Journal of Health Economics 10 (1991): 107-42.
15. Dranove, David, and Meltzer, David. "Do Important Drugs Reach the Market Sooner?" RAND Journal of Economics 25 (1994): 402-23.
16. Ellison, Sara F., et al. "Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins." RAND Journal of Economics 28 (1997): 426-446.
17. European Commission. Commission Communication on the Single Market in Pharmaceuticals. Brussels: European Commission Directorate General III, 1998.
18. Frank, Richard G., and Salkever, David S. "Pricing, Patent Loss and the Market for Pharmaceuticals." Southern Economic Journal 59 (1992): 165-79.
19. Grabowski, Henry G., and Vernon, John M. "Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act." Journal of Law and Economics 35 (1992): 331-50.
20. Grabowski, Henry G., and Vernon, John M. "Prospects for Returns to Pharmaceutical R&D under Health Care Reform." In Competitive Strategies in the Pharmaceutical Industry, edited by Robert B. Helms, pp. 194-207. Washington, D.C.: American Enterprise Institute Press, 1996.
21. Hillman, Alan L., et al. "Financial Incentives and Drug Spending in Managed Care." Health Affairs 18 (1999): 189-200.
22. Reekie, W. Duncan. Medicines Prices and Innovations. London: Institute of Economic Affairs, Health and Welfare Unit, 1996.
23. Reekie, W. Duncan. "Cartels, Spontaneous Price Discrimination and International Pharmacy Retailing." International Journal of the Economics of Business 4 (1997): 279-86.
24. REMIT Consultants. Cost Containment in the European Pharmaceutical Market: New Approaches. London: REMIT Consultants, 1991.
25. Scherer, F. M. "How US Antitrust Can Go Astray: The Brand Name Prescription Drug Litigation." International Journal of the Economics of Business 4 (1997): 239-256.
26. Schoffski, Oliver. "Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany." PharmacoEconomics 10(2) (1996): 37-47.
27. Thomas, Lacy Glenn, II. "Industrial Policy and International Competitiveness in the Pharmaceutical Industry." In Competitive Strategies in the Pharmaceutical Industry, edited by Robert B. Helms, pp. 107-29. Washington, D.C.: American Enterprise Institute Press, 1996.
28. U.S. Congressional Budget Office (CBO). How the Medicaid Rebate on Prescription Drugs Affects Pricing in the Pharmaceutical Industry. Washington, D.C.: CBO, January 1996.
29. U.S. General Accounting Office (GAO). Medicaid: Changes in Best Price for Outpatient Drugs Purchased by HMOs and Hospitals. GAO/HEHS-94-194FS. Washington D.C.: GAO, 1994.
30. Verband Forschender Arzneimittelhersteller (VFA). Statistics '97: The Pharmaceutical Industry in Germany. Bonn: VFA, 1997.
31. Wardell, William M., and Lasagna, Louis. Regulation and Drug Development. Washington, D.C.: American Enterprise Institute Press, 1975.